利福霉素衍生物的研发与肝毒性
Development and hepatotoxicity of rifamycin derivatives.
作者信息
Zhang Jiaojiao, Mattila Joshua, Wipf Peter, Ma Xiaochao
机构信息
Center for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA.
Department of Infectious Diseases and Microbiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.
出版信息
Expert Opin Drug Metab Toxicol. 2025 Jun 29:1-8. doi: 10.1080/17425255.2025.2525451.
INTRODUCTION
Rifamycins are a class of antibiotics crucial for the treatment of tuberculosis (TB). Although the development of rifamycin derivatives has revolutionized TB therapy, they are associated with hepatotoxicity, which limits their clinical use.
AREAS COVERED
This review summarizes the development, clinical applications, and hepatotoxicity of rifamycin derivatives. We highlight the mechanisms of rifamycin drug-induced liver injury (DILI) and discuss strategies to improve the safety profiles of rifamycin derivatives. Relevant literature was reviewed by searching PubMed and SciFinder for articles published up to January 2025.
EXPERT OPINION
The hepatotoxicity of rifamycin derivatives remains a challenge in clinical practice. Further research is needed to clarify the detailed mechanisms of rifamycin-induced liver injury. Mechanism-based strategies are also expected to prevent the toxicity of rifamycin derivatives.
引言
利福霉素是一类对治疗结核病至关重要的抗生素。尽管利福霉素衍生物的研发彻底改变了结核病治疗方法，但它们与肝毒性有关，这限制了它们的临床应用。
涵盖领域
本综述总结了利福霉素衍生物的研发、临床应用及肝毒性。我们强调了利福霉素药物性肝损伤（DILI）的机制，并讨论了改善利福霉素衍生物安全性的策略。通过检索PubMed和SciFinder截至2025年1月发表的文章对相关文献进行了综述。
专家观点
利福霉素衍生物的肝毒性在临床实践中仍然是一个挑战。需要进一步研究以阐明利福霉素诱导肝损伤的详细机制。基于机制的策略也有望预防利福霉素衍生物的毒性。
Zotero 插件